Business
TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16th
About this update from Tg Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021. Details of the data presentations are included below. Poster Presentation Title: TG-1701, A Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies Abstract Book Number: 236 Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CESTLead Author: Chan Y. Cheah MBBS, DMSc, Linear Clinical Research, and Department of Haematology, Sir Charles Gairdner Hospital, Nedlands Western Australia, Medical School, University of Western Australia, Crawley, Western Australia Poster Presentation Title: Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in B-cell non-Hodgkin lymphoma Abstract Book Number: 241 Presentation Available on Demand: Friday, June 18, 2021 at 9:00 CESTLead Author: Gaël Roué, PhD, Lymphoma Translational Group leader, Josep Carreras Leukaemia Research Institute (IJC) The above abstracts are now available in the 16th ICML abstract book, published online at https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.2880. Additional information is available via the ICML meeting website at www.lymphcon.ch. At the time of each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm ABOUT TG THERAPEUTICS, INC.TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active research pipeline including five investigational medicines across these therapeutic areas, TG has received accelerated approval from the U.S. FDA for UKONIQ® (umbralisib), for the treatment of adult patients with relapsed/refractory marginal zone lymphoma who have received at least one prior anti-CD20-based regimen and relapsed/refractory follicular lymphoma who have received at least three prior lines of systemic therapies. Curren...